The efficacy and safety of 225Ac-PSMA-617 in metastatic castration-resistant prostate cancer
In mCRPC, the results indicated that <sup>225</sup>Ac-PSMA-617 demonstrated a favorable disease control rate and relatively minimal side effects. However, additional high-quality randomized controlled trials are required for future validation.
Authors
- Guangfu Liu (ORCID: https://orcid.org/0000-0001-6595-6159)
- Chunyin Zhang (ORCID: https://orcid.org/0000-0003-3003-0094)
- Jiao Ma (ORCID: https://orcid.org/0000-0002-3591-5003)
- Liang Yu (ORCID: https://orcid.org/0009-0007-3922-3454)
- Junzheng Wang
- Jiangchu Yangqing
Institutions
- Southwest Medical University (CN)
- Affiliated Hospital of Southwest Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-02-28
- DOI
- https://doi.org/10.3389/fonc.2025.1516860
- Citations
- 3
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 4.56